Lorazepam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lorazepam: From Anxiety Disorders to Insomnia
One-Sentence Summary
Lorazepam is a benzodiazepine class drug primarily used for anxiety disorders, acute sedation, and seizure management, with well-established GABA-A receptor modulation as its core mechanism. The TxGNN model predicts it may be effective for Insomnia (disease), with 23 clinical trials and 18 publications currently supporting this direction. The mechanistic link is direct — lorazepam’s GABAergic enhancement produces sedative-hypnotic effects that map precisely onto insomnia therapeutic goals, though long-term use carries recognised risks of tolerance and physical dependence.
Note on Top-Ranked Prediction: TxGNN rank 1 (trigeminal nerve neoplasm, score 99.87%) was identified in the repurposing rationale as a likely false positive — a result of indirect knowledge-graph node linkages between “neuropain/neuro-oncology” and “sedatives” with no supporting clinical trial or literature evidence. This report therefore focuses on rank 2 (insomnia), the highest-ranked prediction with actionable evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorders / acute sedation (detailed Malaysia regulatory data not available in this pack) |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L2 |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 5 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Lorazepam is a short-to-intermediate-acting benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors. By binding to the benzodiazepine recognition site at the interface of α and γ subunits, it increases the frequency of chloride ion channel opening in response to GABA, thereby amplifying inhibitory neurotransmission across the central nervous system. Detailed mechanism-of-action data was not available in this evidence pack; however, lorazepam’s dose-dependent CNS depressant profile — covering sedation, anxiolysis, muscle relaxation, and anticonvulsant activity — is extensively documented in the pharmacological literature (PMID 30764).
The mechanistic link between lorazepam and insomnia is both direct and well-grounded. Enhanced GABAergic tone shortens sleep onset latency and prolongs Stage 2 NREM sleep duration, precisely the parameters targeted in insomnia treatment. A head-to-head double-blind crossover RCT (PMID 3280615) demonstrated that lorazepam 2 mg outperformed flurazepam 30 mg on most polysomnographic sleep parameters in chronic insomniacs. Furthermore, Phase 2 and 3 clinical trials of the SM-1 combination (diphenhydramine + zolpidem + lorazepam; NCT03331042, NCT02671760) directly confirmed lorazepam’s contribution to hypnotic efficacy in a transient insomnia model, and a prospective cohort study in 1,400 elderly Taiwanese patients (NCT02648776) assessed real-world risk-benefit outcomes across the hypnotic drug class.
However, long-term use raises clinically important safety concerns: tolerance develops within 1–2 weeks, physical dependence and withdrawal syndrome risk escalates with prolonged use, and lorazepam suppresses slow-wave sleep (SWS). The withdrawn Phase 3 trial (NCT03338764, 0 enrolled) highlights the regulatory and commercial challenges in securing new Phase 3 approval for this indication today. Active deprescribing studies (NCT04572750, NCT06584513, n = 470) reflect the clinical community’s shift toward viewing benzodiazepines as short-term bridges rather than long-term insomnia solutions. Accordingly, any clinical deployment should be restricted to short-term use (< 4 weeks) with mandatory cognitive-behavioural therapy for insomnia (CBT-I) co-integration.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03331042 | Phase 3 | Completed | 85 | 4-way crossover RCT directly evaluating SM-1 (diphenhydramine + zolpidem + lorazepam 0.5 mg delayed-release) vs two active comparators and placebo in a 5-hour phase-advance model of transient insomnia; lorazepam is a core active component |
| NCT02671760 | Phase 2 | Completed | 39 | Phase 2 double-blind PD study of SM-1 (containing lorazepam) on total sleep time in adults with transient insomnia; sleep centre–based evaluation using phase-advance model |
| NCT02648776 | N/A | Unknown | 1,400 | Large prospective cohort (Taiwan) examining medication use patterns, pharmacokinetic and pharmacogenetic characteristics, and clinical outcomes of hypnotics including benzodiazepines in elderly patients; most directly applicable real-world evidence for this drug class in an Asian population |
| NCT03338764 | Phase 3 | Withdrawn | 0 | Phase 3 double-blind placebo-controlled efficacy and safety trial of SM-1 for transient insomnia in adults; withdrawn before enrolment — the withdrawal itself signals the regulatory and commercial headwinds facing new Phase 3 data generation for this indication |
| NCT04396327 | Phase 2 | Not Yet Recruiting | 14 | Phase 2 crossover PD study of SM-1 vs diphenhydramine + lorazepam combination in 3-hour phase-advance model of transient insomnia; directly evaluates lorazepam’s PD contribution |
| NCT04572750 | N/A | Completed | 170 | Electronic self-management intervention to promote benzodiazepine (including lorazepam) cessation in Veterans using BZDs for anxiety and sleep; reflects real-world long-term safety concerns and highlights dependence challenges |
| NCT06584513 | N/A | Recruiting | 470 | BE-SAFE: large patient-centred RCT to reduce benzodiazepine and sedative-hypnotic use in older adults (≥65 years) with sleep problems; underscores contemporary safety management priorities for this drug class |
| NCT03405298 | N/A | Completed | 44 | Pilot RCT of two approaches to chronic benzodiazepine reduction (direct patient education ± behavioural health support) in older adults; demonstrates demand for structured deprescribing protocols |
| NCT00826553 | Phase 1 | Terminated | 6 | Polysomnographic comparison of dexmedetomidine (α₂ agonist) vs GABA agonists (including lorazepam) on sleep stages and total sleep time in mechanically ventilated ICU patients; provides physiological evidence on lorazepam’s effects on sleep architecture |
| NCT02530580 | Phase 1 | Completed | 12 | Phase 1 double-blind crossover PK/PD biomarker study of selective GABA-A modulator AZD7325 vs benzodiazepines including lorazepam; supports mechanistic understanding of GABAergic pharmacology relevant to insomnia |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3280615 | 1988 | RCT | J Clin Pharmacol | Head-to-head double-blind crossover RCT (n=8): lorazepam 2 mg outperformed flurazepam 30 mg on most polysomnographic sleep parameters including sleep latency, stage distribution, and subjective sleep quality over 3 weeks in chronic insomniacs |
| 30625122 | 2018 | Systematic Review | Medical Letter | Current systematic clinical review of drug options for chronic insomnia; positions benzodiazepines (including lorazepam) within the modern treatment landscape relative to Z-drugs, doxepin, suvorexant, and melatonin agonists |
| 10220122 | 1999 | Clinical Trial | Int Clin Psychopharmacol | Compared 24-hour lorazepam dosing (0.5 mg TID) vs single evening dose (1.5 mg HS) in primary insomnia; tested hypothesis that addressing daytime hyperarousal may enhance overall treatment response beyond nocturnal hypnosis alone |
| 41392764 | 2026 | RCT | Food & Function | Probiotic (Bifidobacterium Bbm-19) intervention for insomnia using lorazepam as the pharmacological positive control in a PCPA-induced mouse model; confirms lorazepam as gold-standard benchmark hypnotic agent in current preclinical insomnia research |
| 35087274 | 2022 | Review | J Multidiscip Healthc | Review of efficacy, safety, and drug-drug interactions for insomnia therapy in COVID-19 patients (“coronasomnia”); covers benzodiazepines and summarises interaction risks with antivirals and other COVID medications |
| 36692463 | 2023 | Meta-analysis | Acta Pharmaceutica | Meta-analysis of tranquiliser use across dose types and outcomes in elderly patients with chronic non-communicable diseases; evaluates adverse effects including falls, cognitive impairment, and mortality risk for the benzodiazepine class |
| 19514972 | 2009 | Experimental | Drug Delivery | Comparative intranasal microemulsion study of diazepam, lorazepam, and alprazolam for sleep induction in rats; lorazepam microemulsion demonstrated effective sleep induction, supporting alternative delivery routes for insomnia management |
| 15341891 | 2004 | Cohort | Sleep Medicine | Large managed-care database analysis of hypnotic prescriptions for insomnia; characterises real-world prescribing patterns, patient demographics, and trend shifts from benzodiazepines to non-hypnotic agents over a decade |
| 15040803 | 2004 | Observational | Health Qual Life Outcomes | Survey of sleep quality and sedating drug use (including lorazepam) in acute-care hospitalised adult patients; identifies determinants of hospital-acquired insomnia and characterises the extent of benzodiazepine prescribing for sleep disturbance |
| 23330992 | 2013 | PK Review | Expert Opin Drug Metab Toxicol | Pharmacokinetics review of anxiolytic drugs including lorazepam; covers absorption, distribution, metabolism, elimination, and half-life profiles relevant to optimising dosing regimens for insomnia applications |
Malaysia Market Information
Lorazepam has 5 registered products in Malaysia (market status: ✓ Marketed). Detailed product-level data — including authorization numbers, brand names, dosage forms, and approved indication text — was not captured in this evidence pack.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
To access full registration details, query the National Pharmaceutical Regulatory Agency (NPRA) product database at https://www.npra.gov.my/ using the search term “LORAZEPAM”. Retrieving this data will also resolve Data Gap DG001 (Blocking — required for S1 safety assessment).
Safety Considerations
Please refer to the package insert for safety information.
Data Gap Alert (DG001 — Blocking): Key warnings and contraindication data for the Malaysia-registered lorazepam products were not available in this evidence pack. This constitutes a blocking gap that prevents progression to Safety Stage 1 (S1) evaluation. To resolve: download the prescribing information PDF from the NPRA official source and parse for warnings regarding CNS/respiratory depression, dependence potential, pregnancy/lactation restrictions, and drug interactions.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Lorazepam’s GABA-A receptor mechanism directly and plausibly supports its efficacy in insomnia, underpinned by direct RCT evidence (PMID 3280615), completed Phase 2/3 clinical trial experience with lorazepam-containing combinations (NCT03331042, NCT02671760), and a large real-world prospective cohort study in 1,400 elderly Taiwanese patients (NCT02648776). The drug is already marketed in Malaysia with 5 registered products, substantially lowering the regulatory entry barrier. Evidence level is L2, consistent with a “Proceed with Guardrails” recommendation.
To proceed, the following is needed:
- Resolve Blocking Data Gap DG001: Download and parse the NPRA-registered lorazepam package insert to complete the S1 safety assessment — specifically documenting warnings for CNS/respiratory depression, fall risk in elderly, pregnancy/lactation contraindications, and potential for abuse and physical dependence
- Resolve High-Severity Data Gap DG002: Retrieve full mechanism-of-action profile from DrugBank (DB00186) to formalise the mechanistic rationale section with primary source documentation
- Define short-term use protocol: Establish a maximum treatment duration policy (recommended ≤ 4 weeks) with structured reassessment criteria at each prescription renewal
- Tolerance and dependence monitoring plan: Develop patient education materials covering withdrawal risk, dose tapering schedules, and criteria for escalation to specialist care
- CBT-I co-prescription framework: Design a combination treatment pathway integrating cognitive-behavioural therapy for insomnia as the first-line non-pharmacological backbone, with lorazepam positioned as a short-term adjunct
- Special population risk stratification: Conduct a focused assessment of dose adjustments required for elderly patients (fall risk, cognitive impairment, extended half-life) and patients with respiratory compromise or hepatic impairment
- Contemporary Phase 3 evidence gap: Given the withdrawn NCT03338764 and absence of a completed modern Phase 3 insomnia-specific trial with lorazepam as monotherapy, consider whether a bridging pharmacokinetic or efficacy study is warranted before pursuing any new indication filing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.